Urbánek P, Kristian P, Makara M, Hunyady B, Tomasiewicz K. Epidemiology of HCV infection in the Central European region. Clinical and Experimental Hepatology. 2016;2(1):2-6. doi:10.5114/ceh.2016.58849.
APA
Urbánek, P., Kristian, P., Makara, M., Hunyady, B., & Tomasiewicz, K. (2016). Epidemiology of HCV infection in the Central European region. Clinical and Experimental Hepatology, 2(1), 2-6. https://doi.org/10.5114/ceh.2016.58849
Chicago
Urbánek, Petr, Pavol Kristian, Michael Makara, Bela Hunyady, and Krzysztof Tomasiewicz. 2016. "Epidemiology of HCV infection in the Central European region". Clinical and Experimental Hepatology 2 (1): 2-6. doi:10.5114/ceh.2016.58849.
Harvard
Urbánek, P., Kristian, P., Makara, M., Hunyady, B., and Tomasiewicz, K. (2016). Epidemiology of HCV infection in the Central European region. Clinical and Experimental Hepatology, 2(1), pp.2-6. https://doi.org/10.5114/ceh.2016.58849
MLA
Urbánek, Petr et al. "Epidemiology of HCV infection in the Central European region." Clinical and Experimental Hepatology, vol. 2, no. 1, 2016, pp. 2-6. doi:10.5114/ceh.2016.58849.
Vancouver
Urbánek P, Kristian P, Makara M, Hunyady B, Tomasiewicz K. Epidemiology of HCV infection in the Central European region. Clinical and Experimental Hepatology. 2016;2(1):2-6. doi:10.5114/ceh.2016.58849.
Opinion leaders in each of four countries in the Central European region summarize the available data on hepatitis C virus (HCV) epidemiology. The overall prevalence of anti-HCV antibody reactivity in this region varies between 0.2% and 2.1%, the most prevalent HCV genotype is GT 1. The commonest route of transmission is intravenous drug abuse at present.
